Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
Status:
Completed
Trial end date:
2015-10-13
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to find out more information relating to the highest
dose of KCP-330 that can be given safely and side effects it may cause, to examine how the
body affects KCP-330 concentrations in the blood (pharmacokinetics or PK), to examine the
effects of KCP-330 on the body (pharmacodynamics or PDn) and to obtain information on its
effectiveness in treating cancer.